Log in

NASDAQ:ADAPAdaptimmune Therapeutics News Headlines

$8.06
-0.66 (-7.57 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.89
Now: $8.06
$8.68
50-Day Range
$8.50
MA: $9.32
$10.16
52-Week Range
$0.71
Now: $8.06
$13.40
Volume1.24 million shs
Average Volume870,352 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.33

Headlines

Adaptimmune Therapeutics (NASDAQ ADAP) News Headlines

Source:
DateHeadline
SVB Leerink Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $10.00SVB Leerink Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $10.00
marketbeat.com - August 6 at 11:19 AM
Adaptimmune Therapeutics PLC (ADAP) Q2 2020 Earnings Call TranscriptAdaptimmune Therapeutics PLC (ADAP) Q2 2020 Earnings Call Transcript
nasdaq.com - August 6 at 11:02 PM
SVB Leerink Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $10.00SVB Leerink Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $10.00
americanbankingnews.com - August 6 at 11:15 AM
Adaptimmune Reports Q2 Financial Results and Business UpdateAdaptimmune Reports Q2 Financial Results and Business Update
finance.yahoo.com - August 6 at 8:00 AM
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Insider Sells $44,612.75 in StockAdaptimmune Therapeutics PLC - (NASDAQ:ADAP) Insider Sells $44,612.75 in Stock
americanbankingnews.com - August 5 at 5:28 AM
Adaptimmune Therapeutics (ADAP) Set to Announce Quarterly Earnings on ThursdayAdaptimmune Therapeutics (ADAP) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - July 30 at 4:05 AM
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Receives Consensus Recommendation of "Buy" from AnalystsAdaptimmune Therapeutics PLC - (NASDAQ:ADAP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 28 at 3:38 AM
Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 6.2%Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Down 6.2%
www.americanbankingnews.com - July 23 at 7:44 PM
Adaptimmunes ADP-A2M4 nabs accelerated review in EU for soft tissue cancerAdaptimmune's ADP-A2M4 nabs accelerated review in EU for soft tissue cancer
seekingalpha.com - July 23 at 7:43 PM
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial SarcomaAdaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
finance.yahoo.com - July 23 at 7:43 PM
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020
finance.yahoo.com - July 22 at 9:34 AM
$950,000.00 in Sales Expected for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) This Quarter$950,000.00 in Sales Expected for Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) This Quarter
www.americanbankingnews.com - July 21 at 3:58 AM
Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Up 5.3%Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Up 5.3%
www.americanbankingnews.com - July 20 at 7:46 PM
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Expected to Announce Earnings of -$0.24 Per ShareAdaptimmune Therapeutics PLC - (NASDAQ:ADAP) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - July 19 at 6:42 AM
Should You Buy Adaptimmune Therapeutics plc (ADAP)?Should You Buy Adaptimmune Therapeutics plc (ADAP)?
finance.yahoo.com - July 5 at 5:33 PM
First Week of August 21st Options Trading For Adaptimmune Therapeutics (ADAP)First Week of August 21st Options Trading For Adaptimmune Therapeutics (ADAP)
www.nasdaq.com - June 29 at 3:01 PM
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong IndustryHow Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry
www.nasdaq.com - June 17 at 12:19 PM
Is Adaptimmune Therapeutics a Buy?Is Adaptimmune Therapeutics a Buy?
finance.yahoo.com - June 12 at 8:05 AM
Wayne biopharm firm raises $20M to advance lead drug candidateWayne biopharm firm raises $20M to advance lead drug candidate
www.bizjournals.com - June 10 at 1:09 PM
Why Adaptimmune Therapeutics Stock Crushed It in MayWhy Adaptimmune Therapeutics Stock Crushed It in May
finance.yahoo.com - June 8 at 1:27 PM
Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Companys Board of DirectorsAffinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company's Board of Directors
www.marketwatch.com - June 8 at 8:26 AM
Adaptimmune prices ADS offering at $11Adaptimmune prices ADS offering at $11
seekingalpha.com - June 2 at 7:59 AM
Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock?
finance.yahoo.com - June 2 at 7:59 AM
Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTDAdaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD
finance.yahoo.com - June 2 at 7:59 AM
BRIEF-Adaptimmune Therapeutics PLC Prices Public Offering Of American Depositary SharesBRIEF-Adaptimmune Therapeutics PLC Prices Public Offering Of American Depositary Shares
www.reuters.com - June 2 at 12:56 AM
Party Time: Brokers Just Made Major Increases To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Earnings ForecastsParty Time: Brokers Just Made Major Increases To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Earnings Forecasts
finance.yahoo.com - June 1 at 2:54 PM
Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded TodayWhy Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today
finance.yahoo.com - June 1 at 2:54 PM
Adaptimmune readies ADS offeringAdaptimmune readies ADS offering
seekingalpha.com - June 1 at 9:26 AM
Adaptimmunes stock tumbles after plans for public stock offeringAdaptimmune's stock tumbles after plans for public stock offering
finance.yahoo.com - June 1 at 9:26 AM
Adaptimmune Spikes 127% Post-ASCO; Analyst Triples Price TargetAdaptimmune Spikes 127% Post-ASCO; Analyst Triples Price Target
finance.yahoo.com - June 1 at 4:26 AM
Heres Why Adaptimmune Therapeutics Is Rocketing Higher TodayHere's Why Adaptimmune Therapeutics Is Rocketing Higher Today
finance.yahoo.com - May 29 at 5:32 PM
The Dow Slipped 18 Points Because Trump Pulled His Punches on ChinaThe Dow Slipped 18 Points Because Trump Pulled His Punches on China
finance.yahoo.com - May 29 at 5:32 PM
Adaptimmune Therapeutics Makes a Big Splash at ASCOAdaptimmune Therapeutics Makes a Big Splash at ASCO
www.msn.com - May 29 at 12:32 PM
Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?
www.prnewswire.com - May 29 at 12:32 PM
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ CancerSPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers – Late Stage Development Initiated in EGJ Cancer
finance.yahoo.com - May 29 at 12:31 PM
Adaptimmune Stock Doubles on Positive Cancer Drug DataAdaptimmune Stock Doubles on Positive Cancer Drug Data
finance.yahoo.com - May 29 at 12:31 PM
Traders Sift Through Virtual Cancer Meeting’s Winners and LosersTraders Sift Through Virtual Cancer Meeting’s Winners and Losers
finance.yahoo.com - May 29 at 12:31 PM
Where Will Adaptimmune Be in 5 Years?Where Will Adaptimmune Be in 5 Years?
finance.yahoo.com - May 19 at 8:04 AM
Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMTEdited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMT
finance.yahoo.com - May 15 at 9:53 AM
Cancer Gene Therapy Market Size Outlook 2020 to 2025: Market Trends, Segmentation, Growth Rate and Competitive Landscape with COVID-19 OutbreakCancer Gene Therapy Market Size Outlook 2020 to 2025: Market Trends, Segmentation, Growth Rate and Competitive Landscape with COVID-19 Outbreak
www.marketwatch.com - May 15 at 4:52 AM
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2020 Results - Earnings Call TranscriptAdaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 5:38 PM
Thinking about buying stock in Adaptimmune Therapeutics, Upwork, Eldorado Resorts, Co-Diagnostics, or Delta Air Lines?Thinking about buying stock in Adaptimmune Therapeutics, Upwork, Eldorado Resorts, Co-Diagnostics, or Delta Air Lines?
www.marketwatch.com - May 14 at 12:38 PM
Region set to add thousands of new cell and gene therapy jobs in decade ahead, study saysRegion set to add thousands of new cell and gene therapy jobs in decade ahead, study says
www.bizjournals.com - May 14 at 12:38 PM
Adaptimmune Reports Q1 Financial ResultsAdaptimmune Reports Q1 Financial Results
finance.yahoo.com - May 14 at 12:38 PM
Recap: Adaptimmune Therapeutics Q1 EarningsRecap: Adaptimmune Therapeutics Q1 Earnings
finance.yahoo.com - May 14 at 12:38 PM
Adaptimmune Therapeutics PLC (ADAP) Q1 2020 Earnings Call TranscriptAdaptimmune Therapeutics PLC (ADAP) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 14 at 12:38 PM
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual MeetingSPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
finance.yahoo.com - May 12 at 8:34 AM
BRIEF-Adaptimmune Therapeutics To Rely On SEC Order To Delay Filing Of Its Quarterly Report On Form 10-QBRIEF-Adaptimmune Therapeutics To Rely On SEC Order To Delay Filing Of Its Quarterly Report On Form 10-Q
www.reuters.com - April 29 at 1:58 PM
Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020
finance.yahoo.com - April 29 at 8:58 AM
Adaptimmunes ADP-A2M4 an Orphan Drug in Europe for soft tissue cancerAdaptimmune's ADP-A2M4 an Orphan Drug in Europe for soft tissue cancer
seekingalpha.com - April 28 at 12:55 PM
BRIEF-EMA Committee for Orphan Medicinal Products adopts positive opinion for Orphan Drug Designation for ADP-A2M4 -Adaptimmune TherapeuticsBRIEF-EMA Committee for Orphan Medicinal Products adopts positive opinion for Orphan Drug Designation for ADP-A2M4 -Adaptimmune Therapeutics
www.reuters.com - April 28 at 12:55 PM
This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.